Rapid commercial validation has been achieved through key partnerships disrupting high value/high growth marketsLeadership team realigned in order to enable execution of ancillary protein strategyDyadic is well positioned to seize on geopolitical tailwinds driving reshoring/friendshoring of biomanufacturing supply chains to the United States and allies abroad JUPITER, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI) today annou ...

Dyadic International (DYAI) Q1 2025 Earnings Call May 14, 2025 05:00 PM ET Speaker0 Evening, and welcome to the Dyadic International First Quarter twenty twenty five Financial Results Conference Call. Currently, all participants are in a listen only mode. Following management's prepared remarks, there will be a brief question and answer session. As a reminder, this call is being recorded today, 05/14/2025. I would now like to turn the call over to miss Ping Rawson, Dyadic's chief financial officer. Please g ...

Exhibit 99.1 Dyadic Reports First Quarter 2025 Financial Results and Highlights of Recent Company Progress JUPITER, Fla., May 14, 2025 — Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a biotechnology company specializing in the development of functional recombinant solutions and proprietary production strains to manufacture large quantities of precision-engineered proteins and enzymes for use in life science, nutrition, and industrial applications, today announced ...

(Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to ______ Commission File Number: 000-55264 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q DYADIC INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) | Delaware | 45-0486747 | | - ...

Expanded life science and industrial portfolio with six additional life science products in developmentAdvances toward commercialization of functional recombinant solutions for cell culture media, nucleic and industrial enzyme marketsUp to $4.5 million research grant awarded from the Coalition for Epidemic Preparedness (CEPI)Launched research for $3.0 million Gates Foundation grant for malaria and RSV antibody programsSelected to participate in the inaugural meeting of the "European Vaccines Hub for Pandemi ...

Core Viewpoint - Dyadic International, Inc. is set to report its financial results for the first quarter of 2025 and will host a corporate update conference call on May 14, 2025 [1] Company Overview - Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for human and animal vaccines, therapeutics, and non-pharmaceutical applications such as food and industrial uses [4][6] - The company utilizes microbial gene expression and protein production platforms based on the fungus Thermothelomyces heterothallica, with its lead platform being the C1-cell protein production platform [5] Upcoming Conference Call - The conference call is scheduled for May 14, 2025, at 5:00 p.m. Eastern Time, with dial-in numbers provided for both toll-free and international participants [2] - A webcast link will be available for the live event, and an archive will be accessible within 24 hours [2] Contact Information - For inquiries, the Chief Financial Officer, Ping W. Rawson, can be contacted via phone or email [8]

Core Viewpoint - Dyadic International, Inc. is advancing its proprietary C1 expression platform for the production of non-mRNA antigens, aiming to address global health challenges such as avian influenza and future pandemics through efficient biomanufacturing [1][3]. Company Overview - Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for human and animal vaccines, therapeutics, and non-pharmaceutical applications including food and wellness [4][5]. - The company utilizes microbial production platforms, particularly the C1-cell protein production platform based on the fungus Thermothelomyces heterothallica, to enhance the development and reduce costs of biologic vaccines and drugs [5][6]. Upcoming Presentation - CEO Mark Emalfarb will present at the 2025 World Vaccine Congress in Washington, D.C., discussing the urgent need for smarter biomanufacturing in relation to avian influenza and future pandemics [2][3]. - The presentation will include recent preclinical research data demonstrating the effectiveness of Dyadic's C1 platform in producing non-mRNA antigens that generate high neutralizing antibodies [3]. Strategic Focus - Dyadic is leveraging its microbial platform technologies for various applications, including human and animal vaccines, therapeutics, and food-related products, to meet the growing demand for rapid-response solutions in global health [6].

Financial Data and Key Metrics Changes - As of December 31, 2024, cash, cash equivalents, and investment-grade securities increased to approximately $9.3 million from $7.3 million as of December 31, 2023 [35] - Revenue for the year ended December 31, 2024, rose to approximately $3.495 million compared to $2.899 million the previous year, driven by license revenue of $1 million from ProLiant and approximately $890,000 from enzymes [35][36] - Loss from operations decreased to approximately $5.901 million in 2024 from $8.230 million in 2023, while net loss was approximately $5.809 million or $0.20 per share compared to a net loss of $6.795 million or $0.24 per share the previous year [39] Business Line Data and Key Metrics Changes - The company emphasized strong revenue performance from non-pharmaceutical products, particularly in alternative proteins and life sciences, with significant progress in recombinant human serum albumin and transferrin [8][14] - Recombinant human serum albumin is on track for commercial launch in 2025, while recombinant transferrin is showing promising results in initial studies [14][15] - The dairy enzyme portfolio achieved a productivity milestone of $425,000 in 2024, with a commercial launch anticipated in late 2025 [18] Market Data and Key Metrics Changes - The human albumin market is approximately $5.6 billion and is expected to grow at double digits annually, driven by increased vaccine production [106] - The DNase I and DNA ligase market is around $900 million, also growing at nearly double digits per year [106] - The non-animal dairy proteins market is valued at $26 billion, indicating significant opportunities for products like alpha-lactalbumin and lactoferrin [107] Company Strategy and Development Direction - The company is focused on near-term product commercialization and technology licensing, aiming to capitalize on immediate revenue opportunities while building a robust biopharmaceutical pipeline [7][10] - Dyadic is strengthening its global impact through partnerships with various organizations, including CEPI and the Gates Foundation, to enhance the development and adoption of its C1 platform for vaccines and treatments [11][25] - The dual-track strategy involves commercializing non-pharmaceutical products while advancing mid- to long-term opportunities in human and animal health [9][24] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growing interest in the company's platforms and products, highlighting the potential for significant revenue generation from upcoming commercial launches [50][112] - The company is committed to ensuring high-quality product specifications before market entry, particularly for recombinant products [56] - Management noted that the current environment has shifted focus towards non-pharmaceutical applications to drive revenues sooner, while still pursuing funding opportunities for pharmaceutical developments [117] Other Important Information - The company received a $3 million grant from the Gates Foundation in November 2024 and a $4.5 million grant from CEPI, which will support the development of recombinant protein vaccines [40][26] - Dyadic is actively pursuing additional grant applications to expand the development of its C1 platform across various vaccine and antibody programs [27][29] Q&A Session Summary Question: Can you explain the Gates Foundation and CEPI grants and their significance? - Management confirmed ongoing interest from both organizations and highlighted the importance of these grants in advancing the company's platform and products [45][46] Question: What is the status of albumin commercialization? - Management indicated that progress is being made towards commercialization, with expectations to launch in early 2025 [52][54] Question: Can you clarify the components of research and development revenue? - Management explained that a significant portion of R&D expenses is covered by grants, allowing for profit margins [61] Question: What is the market size opportunity for various products? - Management provided insights into the market sizes for human albumin, DNase I, and non-animal dairy proteins, emphasizing the high-value segments being targeted [106][107] Question: What is the status of the collaboration with Rubicon in South Africa? - Management noted that Rubicon is currently focusing on animal health vaccines, with potential clinical studies expected by the end of the year [119][120]

Dyadic International, Inc. (NASDAQ:DYAI) Q4 2024 Earnings Conference Call March 26, 2025 5:00 PM ET Company Participants Ping Rawson - Chief Financial Officer Mark Emalfarb - President & Chief Executive Officer Joe Hazelton - Chief Operating Officer Conference Call Participants John Vandermosten - Zacks Small Capital Research Vernon Bernardino - HC Wainwright Dick Williams - Williams Resource Group Operator Good evening. And welcome to Dyadic International's year-end 2024 conference call. Currently, all par ...

Exhibit 99.1 DYADIC REPORTS 2024 YEAR-END FINANCIAL RESULTS AND BUSINESS UPDATES JUPITER, FL / March 26, 2025 (GLOBAL NEWSWIRE) Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non- pharmaceutical applications including food, nutrition, and wellness, today announced its financial results for the full year 2024, hig ...